Gastrin-specific interfering RNA

Details for Australian Patent Application No. 2005270917 (hide)

Owner Receptor Biologicx Inc.

Inventors Grabowska, Anna; Watson, Susan A.

Agent Spruson & Ferguson

Pub. Number AU-A-2005270917

PCT Pub. Number WO2006/016275

Priority 60/600,696 11.08.04 US

Filing date 10 August 2005

Wipo publication date 16 February 2006

International Classifications

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

C07K 14/595 (2006.01) Peptides having more than 20 amino acids

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

Event Publications

22 March 2007 PCT application entered the National Phase

  PCT publication WO2006/016275 Priority application(s): WO2006/016275

26 April 2007 Corrigenda

  PCT applications that have entered the National Phase - Name Index Under the name Receptor Biologicx Inc., Application No. 2005270917, under INID(71), correct to read the name Receptor BioLogix, Inc.

21 April 2011 Assignment before Grant

  Receptor BioLogix, Inc. The application has been assigned to Cancer Advances, Inc.

8 March 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005270918-Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor

2005270904-Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor